337 related articles for article (PubMed ID: 23093902)
1. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
[TBL] [Abstract][Full Text] [Related]
3. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
[TBL] [Abstract][Full Text] [Related]
4. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
5. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
6. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
[TBL] [Abstract][Full Text] [Related]
7. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
8. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
[TBL] [Abstract][Full Text] [Related]
9. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
Zhao C; Feng Q; Dou Z; Yuan W; Sui C; Zhang X; Xia G; Sun H; Ma J
PLoS One; 2013; 8(9):e73860. PubMed ID: 24040096
[TBL] [Abstract][Full Text] [Related]
10. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
[TBL] [Abstract][Full Text] [Related]
11. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
12. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
14. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract][Full Text] [Related]
15. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
16. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide releasing d-α-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin.
Song Q; Tan S; Zhuang X; Guo Y; Zhao Y; Wu T; Ye Q; Si L; Zhang Z
Mol Pharm; 2014 Nov; 11(11):4118-29. PubMed ID: 25222114
[TBL] [Abstract][Full Text] [Related]
18. Preparation of a dual cored hepatoma-specific star glycopolymer nanogel via arm-first ATRP approach.
Lou S; Zhang X; Zhang M; Ji S; Wang W; Zhang J; Li C; Kong D
Int J Nanomedicine; 2017; 12():3653-3664. PubMed ID: 28553105
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma.
Wang QS; Gao LN; Zhu XN; Zhang Y; Zhang CN; Xu D; Cui YL
Theranostics; 2019; 9(21):6239-6255. PubMed ID: 31534548
[TBL] [Abstract][Full Text] [Related]
20. Nanomicelles based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake.
Xu Y; Lu Y; Wang L; Lu W; Huang J; Muir B; Yu J
Colloids Surf B Biointerfaces; 2016 May; 141():318-326. PubMed ID: 26874117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
